JAK Inhibitor Benefits in Type 1 Diabetes Lost After Discontinuation

By News Health
1 month Ago

(MedPage Today) — The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed.
After treatment was stopped, C-peptide…

Source link : https://www.medpagetoday.com/meetingcoverage/easd/117538

Author :

Publish date : 2025-09-18 22:01:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

A Health Policy 'Haunted House'; The Unit Menace; Feeling 'Mid' in Medical School?

Novel Oral miR-124 Enhancer Improves Remission in Refractory UC

Study Homes In on Breast Cancer Risk With Hormonal Birth Control

Sex-Life Satisfaction With IBD; Sugar Rationing and Liver Disease; Risky Barrett's

Is the Mediterranean Diet Best First-Line Option for IBS?

Patients Go Without Treatment After Government Shutdown Disrupts Telehealth